Assenagon Asset Management S.A. Takes Position in Repligen Corporation $RGEN

Assenagon Asset Management S.A. purchased a new position in Repligen Corporation (NASDAQ:RGEN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 40,569 shares of the biotechnology company’s stock, valued at approximately $5,423,000. Assenagon Asset Management S.A. owned 0.07% of Repligen at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Alliancebernstein L.P. increased its position in shares of Repligen by 1.3% in the first quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company’s stock valued at $130,317,000 after acquiring an additional 13,284 shares during the period. Brown Capital Management LLC lifted its holdings in Repligen by 16.3% in the second quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock worth $125,036,000 after buying an additional 141,241 shares during the period. Northern Trust Corp boosted its position in Repligen by 1.0% during the 1st quarter. Northern Trust Corp now owns 498,447 shares of the biotechnology company’s stock valued at $63,422,000 after acquiring an additional 4,734 shares in the last quarter. Geneva Capital Management LLC lifted its stake in shares of Repligen by 239.6% in the 2nd quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock valued at $60,639,000 after purchasing an additional 343,991 shares during the period. Finally, Alyeska Investment Group L.P. raised its holdings in Repligen by 24.0% in the first quarter. Alyeska Investment Group L.P. now owns 460,237 shares of the biotechnology company’s stock worth $58,561,000 after purchasing an additional 89,057 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 20,000 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the completion of the sale, the director directly owned 80,743 shares of the company’s stock, valued at $12,483,675.23. This trade represents a 19.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Karen A. Dawes sold 275 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 49,657 shares of company stock valued at $7,721,077. 1.20% of the stock is owned by company insiders.

Repligen Price Performance

NASDAQ RGEN opened at $162.38 on Monday. The business’s fifty day moving average is $157.09 and its 200 day moving average is $135.99. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The company has a market capitalization of $9.14 billion, a PE ratio of 8,123.06, a price-to-earnings-growth ratio of 3.65 and a beta of 1.11.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.42 by $0.04. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The firm had revenue of $188.81 million for the quarter, compared to the consensus estimate of $181.23 million. During the same quarter last year, the company earned $0.43 earnings per share. The business’s revenue for the quarter was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Sell-side analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

RGEN has been the topic of several research reports. Canaccord Genuity Group boosted their price objective on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Wednesday, October 29th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Repligen in a report on Monday, December 15th. Barclays raised their price target on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a report on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $177.92.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.